PAVmed (PAVM) Receiving Somewhat Favorable Press Coverage, Accern Reports
Press coverage about PAVmed (NASDAQ:PAVM) has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PAVmed earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the company an impact score of 49.4829530074408 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, ValuEngine lowered shares of PAVmed from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th.
Shares of PAVmed (NASDAQ:PAVM) opened at 4.00 on Tuesday. The stock’s market capitalization is $53.32 million. The company has a 50-day moving average of $3.76 and a 200 day moving average of $4.81. PAVmed has a one year low of $2.54 and a one year high of $14.49.
PAVmed (NASDAQ:PAVM) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. Equities research analysts forecast that PAVmed will post ($0.72) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “PAVmed (PAVM) Receiving Somewhat Favorable Press Coverage, Accern Reports” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/22/pavmed-pavm-receiving-somewhat-favorable-press-coverage-accern-reports.html.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Stock Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related stocks with our FREE daily email newsletter.